Adverse	adverse	O	B_disease
effects	effects	O	I_disease
of	of	O	O
the	the	O	O
atypical	atypical	O	O
antipsychotics	antipsychotics	S_chemicals	O
.	.	O	O

Collaborative	collaborative	O	O
Working	working	O	O
Group	group	O	O
on	on	O	O
Clinical	clinical	O	O
Trial	trial	O	O
Evaluations	evaluations	O	O
.	.	O	O

Adverse	adverse	O	B_disease
effects	effects	O	I_disease
of	of	O	O
antipsychotics	antipsychotics	S_chemicals	O
often	often	O	O
lead	lead	O	O
to	to	O	O
noncompliance	noncompliance	O	O
.	.	O	O

Thus	thus	O	O
,	,	O	O
clinicians	clinicians	O	O
should	should	O	O
address	address	O	O
patients	patients	O	O
'	'	O	O
concerns	concerns	O	O
about	about	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
and	and	O	O
attempt	attempt	O	O
to	to	O	O
choose	choose	O	O
medications	medications	O	O
that	that	O	O
will	will	O	O
improve	improve	O	O
their	their	O	O
patients	patients	O	O
'	'	O	O
quality	quality	O	O
of	of	O	O
life	life	O	O
as	as	O	O
well	well	O	O
as	as	O	O
overall	overall	O	O
health	health	O	O
.	.	O	O

The	the	O	O
side	side	O	B_disease
effect	effect	O	I_disease
profiles	profiles	O	O
of	of	O	O
the	the	O	O
atypical	atypical	O	O
antipsychotics	antipsychotics	S_chemicals	O
are	are	O	O
more	more	O	O
advantageous	advantageous	O	O
than	than	O	O
those	those	O	O
of	of	O	O
the	the	O	O
conventional	conventional	O	O
neuroleptics	neuroleptics	S_chemicals	O
.	.	O	O

Conventional	conventional	O	O
agents	agents	O	O
are	are	O	O
associated	associated	O	O
with	with	O	O
unwanted	unwanted	O	O
central	central	O	B_disease
nervous	nervous	O	B_disease
system	system	O	I_disease
effects	effects	O	O
,	,	O	O
including	including	O	O
extrapyramidal	extrapyramidal	O	S_disease
symptoms	symptoms	O	O
(	(	O	O
EPS	eps	O	O
)	)	O	O
,	,	O	O
tardive	tardive	O	B_disease
dyskinesia	dyskinesia	O	S_disease
,	,	O	O
sedation	sedation	O	O
,	,	O	O
and	and	O	O
possible	possible	O	O
impairment	impairment	O	O
of	of	O	O
some	some	O	O
cognitive	cognitive	O	O
measures	measures	O	O
,	,	O	O
as	as	O	O
well	well	O	O
as	as	O	O
cardiac	cardiac	O	O
effects	effects	O	O
,	,	O	O
orthostatic	orthostatic	O	B_disease
hypotension	hypotension	O	S_disease
,	,	O	O
hepatic	hepatic	O	O
changes	changes	O	O
,	,	O	O
anticholinergic	anticholinergic	S_chemicals	O
side	side	O	B_disease
effects	effects	O	I_disease
,	,	O	O
sexual	sexual	O	B_disease
dysfunction	dysfunction	O	I_disease
,	,	O	O
and	and	O	O
weight	weight	O	B_disease
gain	gain	O	I_disease
.	.	O	O

The	the	O	O
newer	newer	O	O
atypical	atypical	O	O
agents	agents	O	O
have	have	O	O
a	a	O	O
lower	lower	O	O
risk	risk	O	O
of	of	O	O
EPS	eps	O	O
,	,	O	O
but	but	O	O
are	are	O	O
associated	associated	O	O
in	in	O	O
varying	varying	O	O
degrees	degrees	O	O
with	with	O	O
sedation	sedation	O	O
,	,	O	O
cardiovascular	cardiovascular	O	O
effects	effects	O	O
,	,	O	O
anticholinergic	anticholinergic	S_chemicals	O
effects	effects	O	O
,	,	O	O
weight	weight	O	B_disease
gain	gain	O	I_disease
,	,	O	O
sexual	sexual	O	B_disease
dysfunction	dysfunction	O	I_disease
,	,	O	O
hepatic	hepatic	O	O
effects	effects	O	O
,	,	O	O
lowered	lowered	O	O
seizure	seizure	O	S_disease
threshold	threshold	O	O
(	(	O	O
primarily	primarily	O	O
clozapine	clozapine	O	O
)	)	O	O
,	,	O	O
and	and	O	O
agranulocytosis	agranulocytosis	O	S_disease
(	(	O	O
clozapine	clozapine	O	O
only	only	O	O
)	)	O	O
.	.	O	O

Since	since	O	O
the	the	O	O
incidence	incidence	O	O
and	and	O	O
severity	severity	O	O
of	of	O	O
specific	specific	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
differ	differ	O	O
among	among	O	O
the	the	O	O
various	various	O	O
atypicals	atypicals	O	O
,	,	O	O
the	the	O	O
clinician	clinician	O	O
should	should	O	O
carefully	carefully	O	O
consider	consider	O	O
which	which	O	O
side	side	O	B_disease
effects	effects	O	I_disease
are	are	O	O
most	most	O	O
likely	likely	O	O
to	to	O	O
lead	lead	O	O
to	to	O	O
the	the	O	O
individual	individual	O	O
's	's	O	O
dissatisfaction	dissatisfaction	O	O
and	and	O	O
noncompliance	noncompliance	O	O
before	before	O	O
choosing	choosing	O	O
an	an	O	O
antipsychotic	antipsychotic	S_chemicals	O
for	for	O	O
a	a	O	O
particular	particular	O	O
patient	patient	O	O
.	.	O	O

